Meme Kanseri Tedavisinde Kardiyotoksisite
Özet
Kanser ve kardiyovasküler hastalıklar, tüm dünyada mortalite ve morbiditenin en önemli nedenlerindendir. Tüm dünyada yaklaşık 2 milyon kadını etkileyen meme kanseri, en sık teşhis edilen malignite olarak bilinmektedir. Tanı sonrası 5 yıllık sağ kalım oranı, gelişen tedaviler sayesinde çoğu ülkede %80’lere ulaşmaktadır. Meme kanserinde kullanılan tedaviler uzamış sağ kalım süresi sağlarken bazı tedavilerin kardiyovasküler sistem üzerinde ciddi yan etkileri olabilmektedir. Bununla birlikte tedaviye ilişkin kardiyak yapı ve fonksiyonlarında olumsuz etki yaşayan hastaların sayısında da artış gözlenmiştir. Kardiyovasküler hastalıklar, onkolojik tedavilerden sonra de novo hastalık olarak görülebileceği gibi daha önceden var olan kardiyak hastalığın ilerlediği bir tablo olarak da karşımıza çıkabilmektedir. Daha önce kanser tedavisi öyküsü olan ya da tedavisi halen devam eden hastalarda, kardiyovasküler sağlık en iyi şekilde optimize edilmeli ve tedaviye ilişkin kardiyovasküler komplikasyonlar en aza indirgenmeye çalışılmalıdır. Onkolojik tedavilere bağlı kardiyotoksisiteyi önlemek ve yönetmek için multidisipliner yaklaşıma ihtiyaç vardır.
Referanslar
Valiyaveettil, Deepthi, Deepa Joseph, and Monica Malik. "Cardiotoxicity in breast cancer treatment: Causes and mitigation." Cancer Treatment and Research Communications 37 (2023): 100760.
https://doi.org/10.1016/j.ctarc.2023.100760
Suter, Thomas M., and Michael S. Ewer. "Cancer drugs and the heart: importance and management." European heart journal 34.15 (2013): 1102-1111. https://doi.org/10.1093/eurheartj/ehs181
Florescu, Diana Ruxandra, and Diana Elena Nistor. "Therapy-induced cardiotoxicity in breast cancer patients: a well-known yet unresolved problem." Discoveries (7.1 (2019): e89.)
https://doi.org/10.15190/d.2019.2
Bird, Brian RJ Healey, and Sandra M. Swain. "Cardiac toxicity in breast cancer survivors: review of potential cardiac problems." Clinical cancer research 14.1 (2008): 14-24.
https://doi.org/10.1158/1078-0432.ccr-07-1033
Early Breast Cancer Trialists' Collaborative Group. "Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials." The Lancet 379.9814 (2012): 432-444. https://doi.org/10.1016/s0140-6736(11)61625-5
Swain, Sandra M., Fredrick S. Whaley, and Michael S. Ewer. "Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials." Cancer: Interdisciplinary International Journal of the American Cancer Society 97.11 (2003): 2869-2879.
https://doi.org/10.1002/cncr.11407
Curigliano, Giuseppe, et al. "Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines." Annals of oncology 23 (2012): vii155-vii166.
https://doi.org/10.1093/annonc/mds293
Lyon, Alexander R., et al. "Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the C ardio‐O ncology S tudy G roup of the H eart F ailure A ssociation of the E uropean S ociety of C ardiology in collaboration with the I nternational C ardio‐O ncology S ociety." European journal of heart failure 22.11 (2020): 1945-1960. https://doi.org/10.1002/ejhf.1920
Bikiewicz, Agata, et al. "Adjuvant breast cancer treatments cardiotoxicity and modern methods of detection and prevention of cardiac complications." ESC Heart Failure 8.4 (2021): 2397-2418.
https://doi.org/10.1002/ehf2.13365
McDonagh, Theresa A., et al. "2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC." European heart journal 42.36 (2021): 3599-3726.
https://doi.org/10.1093/eurheartj/ehab368
Dhesi, Sumandeep, et al. "Cyclophosphamide-induced cardiomyopathy: a case report, review, and recommendations for management." Journal of investigative medicine high impact case reports 1.1 (2013): 2324709613480346.
https://doi.org/10.1177/2324709613480346
Iqubal, Ashif, et al. "Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: Old drug with a new vision." Life sciences 218 (2019): 112-131.
https://doi.org/10.1016/j.lfs.2018.12.018
Katayama, Minako, et al. "Fulminant fatal cardiotoxicity following cyclophosphamide therapy." Journal of cardiology 54.2 (2009): 330-334. https://doi.org/10.1016/j.jjcc.2009.01.006
Focaccetti, Chiara, et al. "Effects of 5-fluorouracil on morphology, cell cycle, proliferation, apoptosis, autophagy and ROS production in endothelial cells and cardiomyocytes." PloS one 10.2 (2015): e0115686.
https://doi.org/10.1371/journal.pone.0115686
Shiga, Taro, and Makoto Hiraide. "Cardiotoxicities of 5-fluorouracil and other fluoropyrimidines." Current treatment options in oncology 21.4 (2020): 27.
https://doi.org/10.1007/s11864-020-0719-1
Schlitt, Axel, et al. "Cardiotoxicity and oncological treatments." Deutsches Ärzteblatt International 111.10 (2014): 161.
https://doi.org/10.3238/arztebl.2014.0161
Zagami, Paola, et al. "Cardiotoxicity of agents used in patients with breast cancer." JCO Oncology Practice 20.1 (2024): 38-46.
https://doi.org/10.1200/op.23.00494
Lapeyre‐Mestre, Maryse, et al. "Vinorelbine‐related cardiac events: A meta‐analysis of randomized clinical trials." Fundamental & clinical pharmacology 18.1 (2004): 97-105.
https://doi.org/10.1046/j.0767-3981.2003.00215.x
Gonzalez-Angulo, Ana M., et al. "High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2–positive, node-negative tumors 1 cm or smaller." Journal of clinical oncology 27.34 (2009): 5700-5706. https://doi.org/10.1200/jco.2009.23.2025
Griguolo, G., and V. Guarneri. "Cardiac complications of cancer and anticancer treatment." ESMO Handbook of Oncological Emergencies 2 (2016): 3-16. https://doi.org/10.1007/16833_2022_76
Wu, Qinchao, et al. "The molecular mechanisms of cardiotoxicity induced by HER2, VEGF, and tyrosine kinase inhibitors: an updated review." Cardiovascular Drugs and Therapy (2022): 1-14.
https://doi.org/10.1007/s10557-021-07181-3
Chen, Jersey, et al. "Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer." Journal of the American College of Cardiology 60.24 (2012): 2504-2512.
https://doi.org/10.1016/j.jacc.2012.07.068
Karaca, Mustafa, et al. "Ventricular bigeminal rhythm associated with trastuzumab: A potential cardiac side effect." Journal of cancer research and therapeutics 14.Suppl 2 (2018): S536-S537.
https://doi.org/10.4103/0973-1482.183557
Lee Chuy, Katherine, and Anthony F. Yu. "Cardiotoxicity of contemporary breast cancer treatments." Current treatment options in oncology 20 (2019): 1-16. https://doi.org/10.1007/s11864-019-0646-1
Verma, Sunil, et al. "Trastuzumab emtansine for HER2-positive advanced breast cancer." New England journal of medicine 367.19 (2012): 1783-1791. https://doi.org/10.1056/nejmoa1209124
Pondé, Noam, et al. "Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: pooled analysis in advanced HER2-positive breast cancer." European journal of cancer 126 (2020): 65-73.
https://doi.org/10.1016/j.ejca.2019.11.023
Von Minckwitz, Gunter, et al. "Trastuzumab emtansine for residual invasive HER2-positive breast cancer." New England Journal of Medicine 380.7 (2019): 617-628. https://doi.org/10.1056/nejmoa1814017
Modi, Shanu, et al. "Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low–expressing advanced breast cancer: results from a phase Ib study." Journal of Clinical Oncology 38.17 (2020): 1887-1896.
https://doi.org/10.1200/jco.19.02318
Rugo, Hope S., et al. "Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial." JAMA oncology 7.4 (2021): 573-584.
https://doi.org/10.1001/jamaoncol.2020.7932
Bebero, Katrina Gaelic Moncano, Eric John Arca Marayag, and Eugenio Vistan Regala. "The effect of addition of cyclin-dependent kinase 4 & 6 (CDK 4/6) inhibitor to endocrine therapy in the cardiovascular toxicity in advanced breast cancer patients: A systematic review and meta-analysis." (2019): 134-134.
https://doi.org/10.1200/JGO.2019.5.suppl.134
Finn, Richard S., et al. "Long‐term pooled safety analysis of palbociclib in combination with endocrine therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer: updated analysis with up to 5 years of follow‐up." The Oncologist 26.5 (2021): e749-e755.
https://doi.org/10.1002/onco.13684
Rugo, Hope S., et al. "Management of abemaciclib‐associated adverse events in patients with hormone receptor‐positive, human epidermal growth factor receptor 2‐negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3." The oncologist 26.1 (2021): e53-e65.
https://doi.org/10.1002/onco.13531
Thein, K. Z., et al. "Updated meta-analysis of randomized controlled trials (RCTs) to determine the CDK 4/6 inhibitors associated venous thromboembolism (VTE) risk in hormone receptor-positive breast cancer (BC) patients." Annals of Oncology 29 (2018): viii606. https://doi.org/10.1093/annonc/mdy300.008
Naqash, Abdul Rafeh, et al. "Major adverse cardiac events with immune checkpoint inhibitors: A pooled analysis of trials sponsored by the National Cancer Institute—Cancer Therapy Evaluation Program." Journal of Clinical Oncology 40.29 (2022): 3439-3452. https://doi.org/10.1200/jco.22.00369
Burstein, Harold J., et al. "Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: ASCO clinical practice guideline focused update." Journal of Clinical Oncology 37.5 (2019): 423-438.
https://doi.org/10.1200/jco.18.01160
Frasor, Jonna, et al. "Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells." Cancer research 64.4 (2004): 1522-1533.
https://doi.org/10.1158/0008-5472.can-03-3326
Khosrow-Khavar, F., et al. "Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials." Annals of Oncology 28.3 (2017): 487-496. https://doi.org/10.1093/annonc/mdw673
Khosrow-Khavar, Farzin, et al. "Aromatase inhibitors and the risk of cardiovascular outcomes in women with breast cancer: a population-based cohort study." Circulation 141.7 (2020): 549-559.
https://doi.org/10.1161/CIRCULATIONAHA.119.044750
Di Leo, Angelo, et al. "Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced breast cancer." Journal of Clinical Oncology 28.30 (2010): 4594-4600. https://doi.org/10.1200/JCO.2010.28.8415
Florescu, Diana Ruxandra, and Diana Elena Nistor. "Therapy-induced cardiotoxicity in breast cancer patients: a well-known yet unresolved problem." Discoveries 7.1 (2019): e89. https://doi.org/10.15190/d.2019.2
Darby, Sarah C., et al. "Risk of ischemic heart disease in women after radiotherapy for breast cancer." New England Journal of Medicine 368.11 (2013): 987-998. https://doi.org/10.1056/nejmoa1209825
Baillet, F., et al. "The use of a specific hypofractionated radiation therapy reg imen versus classical fractionation in the treatment of breast cancer: A randomized study of 230 patients." International Journal of Radiation Oncology* Biology* Physics 19.5 (1990): 1131-1133. https://doi.org/10.1016/0360-3016(90)90216-7
Jaworski, Catherine, et al. "Cardiac complications of thoracic irradiation." Journal of the American College of Cardiology 61.23 (2013): 2319-2328. https://doi.org/10.1016/j.jacc.2013.01.090
Demirci, Senem, et al. "Radiation-induced cardiac toxicity after therapy for breast cancer: interaction between treatment era and follow-up duration." International Journal of Radiation Oncology* Biology* Physics 73.4 (2009): 980-987. https://doi.org/10.1016/j.ijrobp.2008.11.016
